Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.57
-0.07 (-0.55%)
At close: Dec 19, 2025, 4:00 PM EST
12.66
+0.09 (0.72%)
After-hours: Dec 19, 2025, 7:55 PM EST
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $784.51M in the quarter ending September 30, 2025, with 11.68% growth. This brings the company's revenue in the last twelve months to $2.93B, up 9.50% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.93B
Revenue Growth
+9.50%
P/S Ratio
1.34
Revenue / Employee
$353,610
Employees
8,300
Market Cap
3.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
| Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
| Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
| Dec 31, 2015 | 866.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AMRX News
- 2 days ago - Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
- 10 days ago - Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewsWire
- 14 days ago - Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease - GlobeNewsWire
- 17 days ago - Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - GlobeNewsWire
- 17 days ago - Amneal to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - GlobeNewsWire
- 5 weeks ago - Amneal Receives U.S. FDA Approval for Iohexol Injection - GlobeNewsWire
- 7 weeks ago - Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript - Seeking Alpha